SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing massive trading volume and a significant surge as investors react to a de-risking FDA update for its ANKTIVA bladder cancer application, which importantly does not require new clinical trials. This news, coupled with recent international approvals and high short interest, has ignited widespread community discussion about a potential short and gamma squeeze. The intense momentum highlights a fervent belief in the drug's long-term potential as a cancer treatment, driving bullish sentiment against a backdrop of active short positions.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is currently trending due to its recent award of a prime contract position on the U.S. Missile Defense Agency's SHIELD program, significantly bolstering its standing in government AI data training. The community is highly bullish on this development, anticipating a major breakout, potential short squeeze, and further expansion into defense and sovereign AI markets, with many viewing the company as undervalued.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to compelling positive Phase 1 data for its oral drug soquelitinib in atopic dermatitis, showcasing strong efficacy in treatment-resistant patients and a favorable safety profile. The community is buzzing about its "best-in-class" potential in a massive market and a possible short squeeze, with many anticipating significant upside or a partnership. Despite the early stage of development, the innovative mechanism is driving substantial investor conversation.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a significant licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as crucial validation for its non-mRNA technology. This development is intensifying community discussions about the stock's high short interest and potential for a squeeze, alongside ongoing pressure from an activist investor for management to expedite further partnerships and unlock core asset value.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is capturing significant attention following multiple analyst upgrades and reports of a substantial U.S. defense contract under the SHIELD program, fueling strong bullish sentiment. The community is actively discussing the stock's ability to maintain its upward momentum against price resistance ahead of its highly anticipated earnings report, with many expecting positive developments from its server CPU demand and foundry initiatives.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to heightened global market uncertainty, fueled by renewed tariff threats against European nations and the ongoing Greenland situation. The community is sharply divided, with some anticipating a familiar "buy the dip" opportunity for the tech-heavy index, while others fear a more sustained market correction if trade tensions further escalate.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as regulatory developments create a mixed outlook: a Massachusetts judge issued a preliminary injunction against prediction market Kalshi, a move seen as highly favorable for traditional sportsbooks. This positive catalyst is juxtaposed with the NCAA's call for a federal halt on college sports betting, intensifying investor debate around regulatory impacts and the rising competition from alternative betting platforms. Community sentiment is also weighing recent analyst upgrades and an increased share buyback authorization, leading to notable stock volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is actively discussed following its announcement of a record date for a digital token initiative, with many anticipating a short squeeze and other upcoming catalysts. This drives significant polarization, as some investors see substantial upside from loyalist support, while others view it as a highly speculative, politically-charged stock susceptible to market volatility and dilution. The stock remains a key talking point, reflecting the strong intersection of media, branding, and political narratives in its trading dynamics.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is captivating attention following its selection for a critical Missile Defense Agency contract vehicle, sparking renewed bullish sentiment within the quantum computing sector. While bulls anticipate further momentum from upcoming industry events like CES, community discussions remain divided between those highlighting its technological advancements and others questioning its current valuation amidst ongoing R&D.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group (TWG) is seeing significant conversation following its announced acquisition of a wine trading business valued at $125 million, to be paid in newly issued shares. This strategic expansion into luxury wine has ignited strong community debate, with investors split between concerns over the share dilution at $7.00 per share and those enthusiastically accumulating the stock on the belief of a future rebound. The intense volatility reflects the mixed sentiment surrounding this low-float entity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?

Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?

'A Hawkish Cut' From Fed? ETFs to Gain 

A hawkish Fed cut sparks shifts in markets. Small-cap value AVUV, mid-cap value RFV, banks KBE and cash-cow plays COWZ look poised to gain.

Beyond Tesla: Why GM and Ford Heavy ETFs Could Be Safer Bets Now?

GM and Ford-focused ETFs like RPV, MADE, and COWZ may offer investors stability as Tesla faces a post-subsidy demand cliff.  

Why Free Cash Flow Drives Superior Stock Performance

Here's why companies with high free cash flow often demonstrate high quality.

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the Health and Human Services Department, led by Robert F. Kennedy Jr., plans to "drastically" cut federal funding for domestic HIV prevention.While cuts have not been finalized, the Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-administration-weighing-major-cuts-to-funding-for-domestic-hiv-prevention-8dcad39b?mod=Searchresults_pos1&amp;page=1&amp;mod=article_inline&amp;adobe_mc=MCMID%3D74537243080012175182679892959762943330%7CMCORGID%3DCB68E4BA55144CAA0A4C98A5%2540AdobeOrg%7CTS%3D1742440495&amp;_gl=1*1myqz7*_gcl_au*NTUzNDY5MDY4LjE3MzUyMTA0MzI.*_ga*MTg1Mzg3MjI1NS4xNzE4OTcyNDYz*_ga_K2H7B9JRSS*MTc0MjQ0MDIzNy4yNi4xLjE3NDI0NDA0OTMuNjAuMC4w">reported</a>, citing people familiar with the matter, that they could be announced soon as part of the Trump administration's broader budget reductions at the Centers for Disease Control and Prevention.Gilead, which has a portfolio of HIV prevention treatments such as Biktarvy and Descovy, risks a hit to revenues if the report turns out to be true.However, retail investors and Wall Street analysts remain largely unfazed for now.Retail sentiment for Gilead on Stocktwits climbed further into the 'extremely bullish' zone on Wednesday, with message volume up 57% following the news.&nbsp;<figure class="image"><img style="aspect-ratio:1318/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/GILD_sentiment_and_message_volume_as_of_March_19_png_baa27803b8.webp" alt="GILD sentiment and message volume as of March 19.png" width="1318" height="302"><figcaption>GILD sentiment and message volume as of March 19. | source: Stocktwits</figcaption></figure>Observers on the platform cited Gilead's dominance in HIV treatments, growing oncology presence, and strong free cash flow as reasons to hold on to the stock.<stembedurl>https://stocktwits.com/Bitcoin333/message/608542775</stembedurl><stembedurl>https://stocktwits.com/skcots131313/message/608543583</stembedurl>According to The Fly, JPMorgan acknowledged that the WSJ report is "clearly not a positive" but says the potential cuts wouldn't impact access to PrEP (pre-exposure prophylaxis). The firm noted that the CDC doesn't reimburse PrEP drugs but funds research and education.&nbsp;The research firm remains bullish on Gilead's lenacapavir — a twice-yearly injectable HIV-1 capsid inhibitor — as a key growth driver and maintains an 'Overweight' rating on the stock.Oppenheimer sees Gilead's pullback as a reaction to uncertainty but doesn't view the funding concerns as a material risk. The firm estimates PrEP revenues account for just 8% of Gilead's total sales, with Medicaid representing an even smaller fraction.&nbsp;It expects early lenacapavir adoption mostly from private insurers and reiterated an 'Outperform' rating with a $132 price target.If approved by the Food and Drug Administration, Morgan Stanley reportedly estimates that lenacapavir could generate annual sales of over $6 billion by 2030.According to Koyfin data, Gilead stock currently trades at a 13.5x forward earnings multiple, compared to Eli Lilly's 36.1x and Amgen's 15.3x.Shares of Gilead are up 16% this year, outperforming the NASDAQ Biotechnology Index's 3% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

Equity

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.


HP, Inc. (<a class="mention" data-mention="$HPQ" data-symbol-id="HPQ" href="https://stocktwits.com/symbol/HPQ" target="_blank">$HPQ</a>) shares fell sharply in Wednesday’s premarket session after the Palo Alto-based company announced fiscal year 2024 fourth-quarter results roughly in line with expectations and running quarter guidance that trailed, reflecting the ongoing weakness in the global PC industry.&nbsp;The manufacturer of personal computing, printing, 3D printing, and gaming products, said its fourth-quarter non-GAAP earnings per share came in at $0.93, within the guidance range of $0.89-$0.99 and in line with the consensus.Net revenue rose a modest 1.7% year-over-year (YoY) to $14.1 billion compared to the $13.99&nbsp;billion consensus estimate. Personal systems net revenue climbed 2% to $9.6 billion,&nbsp;representing around 68% of the total, and printing net revenue was up 1%.Estimates from Gartner&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gartner.com/en/newsroom/press-releases/2024-10-09-gartner-says-worldwide-pc-shipments-declined-1-percent-in-third-quarter-of-2024">showed</a> global PC shipments falling 1.3% YoY to 62.9 million units in the third quarter, with HP’s shipments seeing a marginal YoY drop.Enrique Lores, HP President and CEO, said, "We are pleased with our Q4 performance where we saw revenue growth for the second consecutive quarter, driven by steady progress in Personal Systems and Print."HP said it returned $1.2 billion to shareholders in the form of share repurchase and dividends.&nbsp;The company announced a 5% increase to its annual dividend. The board declared a $0.2894 quarterly dividend, payable on Jan. 2, 2025, to shareholders of record as of Dec. 11, 2024.Looking ahead, HP expects non-GAAP EPS of $0.70-$0.76 for the first quarter of the fiscal year 2025 and $3.45-$3.75 for the full year. Analysts, on average, expect the metrics to come in at $0.82 and $3.60, respectively.&nbsp;CFO Karen Parkhill said, “As we look ahead, we are well positioned to deliver solid growth across revenue, non-GAAP net earnings, EPS and free cash flow in FY25.”As of 8:30 a.m. ET in premarket trading, HP shares were trading down 8.26% at $35.87. The stock, though, has gained over 33% so far this year.<figure class="image"><a href="https://stocktwits.com/symbol/HPQ"><img style="aspect-ratio:630/131;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/hp_sentiment_df3a5935b3.png" alt="hp-sentiment.png" width="630" height="131"></a><figcaption>HP sentiment and message volume November 25, 2024, premarket as of 8:30 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits platform, sentiment toward the stock flipped to ‘extremely bearish’ (5/100) from ‘extremely bullish,’&nbsp;marking a year-low. Meanwhile, message volume&nbsp;climbed further into the&nbsp;‘extremely high’&nbsp;(97/100) territory, the highest it has been this year.Rival Dell Technologies, Inc. ($DELL), despite the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dell-q3-2025-earnings-beat-estimates-revenue-trails/cJI0ul9RW3">post-earnings plunge,</a> was viewed more positively by retailers, given its exposure to artificial intelligence servers.&nbsp;For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rambus-initiated-at-outperform-at-baird/cJIWrizRgU">Rambus Stock Powers Up After Memory Chipmaker Snags A Bullish Rating: Retail Upbeat</a>

Global PC shipments fell 1.3% YoY in Q3, according to Gartner.

HP Q4 Results Deflate Retail Mood: Stock Sinks Over 8% As In-Line Quarterly Results, Sub-par Guidance Worry Traders

HP reported low single-digit revenue growth for its personal systems as well as printing segments.

ZoomInfo Technologies, Inc. ($ZI), a B2B platform that offers a commercial search-engine for companies and businesses, reported third-quarter results that exceeded expectations and issued fairly in-line guidance for the fourth quarter and the full year.Vancouver, Washington-based ZoomInfo reported third-quarter non-GAAP earnings per share of $0.28, up from $0.26 earned a year-ago. The bottom-line result exceeded the consensus estimate of $0.22.Revenue, however, fell 3% year-over-year (YoY) to $303.6 million and yet surpassed the $299.36-million consensus estimate.Henry Schuck, ZoomInfo founder and CEO, said, "We continued our move up-market, fueled by ZoomInfo Copilot and Operations growth, and we delivered strong financial results while improving the quality of new customers that we are bringing in.""The entire company is more focused than ever on delighting both our new and existing users via robust product innovation and customer obsession."The company noted that net revenue retention was stable for the third consecutive quarter, as it grew its $100,000 and million-dollar customer cohorts yet again.&nbsp;Looking ahead, the company narrowed its full-year revenue guidance from $1.19 billion-$1.205 billion to $1.201 billion-$1.204 billion. It raised its non-GAAP EPS guidance from $0.86-$0.88 to $0.92-$0.93.&nbsp;Analysts, on average, expect revenue of $1.2 billion and non-GAAP EPS of $0.90.ZoomInfo guided to fourth-quarter revenue of $296 million-$299 million and non-GAAP EPS of $0.22-$0.23. This compares to the consensus estimates of $296.91 million and $0.23, respectively.Following the results, Mizuho raised the price target for the stock from $9 to $11 while maintaining a Neutral rating, the Fly&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=ZI">reported.</a> The firm described the quarter as "healthy," and also noted that the management sees small business write-offs abating.&nbsp;The company was seeing traction with its artificial intelligence offerings and the CoPilot solution, especially with mid-market and enterprise segments, the firm added.Retailers on the Stocktwits platform were mixed about the stock. One of them said the company is struggling in one of the best macro environments in history.<stembedurl>https://stocktwits.com/ASAP17/message/592252559</stembedurl>Another termed the stock as a “catch-up play” and noted that the short interest was high.<stembedurl>https://stocktwits.com/Chickenstick1/message/592245466</stembedurl>In premarket trading as of 8:40 am ET, the stock was down a steep 12.84% to $11.40.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cava-reports-2024-q3-beat-lifts-guidance/cJ4jPR2ROH">CAVA Stock Soars As Tasty Q3 Results Earn Wall Street Cheers, But Retail Appetite Mixed</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

ZoomInfo said net revenue retention was stable for the third consecutive quarter. 

ZoomInfo Stock Plunges Despite Q3 Beat As Traders Fret Over Shrinking Revenue: Retail Remains Wary

ZoomInfo CEO Schuck said the company is focused on satisfying new and existing customers through product innovation and customer obsession.

Shares of Lyft, Inc. (<a class="mention" data-mention="$LYFT" data-symbol-id="LYFT" href="https://stocktwits.com/symbol/LYFT" target="_blank">$LYFT</a>) shot up more than 20% pre-market Thursday, adding to previous session gains and boosting retail sentiment. The company reported third-quarter sales that beat expectations and offered an upbeat demand forecast.For Q3, Lyft posted a net loss of $12.4 million, or $0.03 per share (which included a $36.4 million restructuring charge), in line with Wall Street estimates. Revenue rose 32% to $1.52 billion from a year earlier, better than the expected $1.44 billion.Lyft reported record active riders of 24.4 million for the quarter, a 9% increase year-over-year, and record rides of 217 million, up 16% from a year earlier.In Q3, Lyft said demand exceeded expectations, and added that it ended the quarter with a strong cash position of $770 million. Lyft has a long-term debt of $574 million.The company expects full-year free cash flow to exceed $650 million and noted that it executed all parts of its strategic plan during the quarter.&nbsp;It said its price lock feature performed better than expected, with driver and rider metrics hitting all-time highs.&nbsp;Lyft also reported commute rides surpassing pre-pandemic levels and projected further expansion in Canada.&nbsp;For FY24, the company reaffirmed mid-teens rides growth and forecasted gross bookings growth around 17%.&nbsp;For Q4, it expects adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $100 million–$105 million and gross bookings of $4.28 billion–$4.35 billion.The company also unveiled multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-stock-in-focus-after-multiple-av-partnership-announcements/cJ4TGmrR9z">autonomous vehicle (AV) partnerships</a>, including alliances with Mobileye and Nexar, prior to its earnings release, driving up retail excitement.<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_07_at_5_00_49_PM_6ec1047ebf.png" alt="Screenshot 2024-11-07 at 5.00.49 PM.png" width="1318" height="318"><figcaption>LYFT sentiment and message volume on Nov 7 as of 6:45 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, LYFT stock sentiment was ‘extremely bullish’ going into Thursday amid rising retail chatter. The ticker was among the top trending symbols as of 6:45 am ET.One user hoped the stock “sticks to the upside” following the results, while another expected it to hit $20 by Friday.<stembedurl>https://stocktwits.com/tkathlina/message/591534163</stembedurl><stembedurl>https://stocktwits.com/NooBeeBee/message/591522981</stembedurl>Lyft shares are up over 4% so far this year, and if Thursday’s pre-market gains hold, the stock could be on track to hit near 6-month highs.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/geo-cxw-stocks-surge-on-trump-detention-policies/cJ4Tb1eR9C">Prison Stocks Geo Group, Core Civic Surge To 5-Year Highs: Retail Bets Big On Trump-Driven Detention Boom</a>

Lyft said its price lock feature performed better than expected, with driver and rider metrics hitting all-time highs. 

Lyft Stock Wins Over Wall Street And Retail With Q3 Revenue Beat And AV Alliances

The company reported commute rides surpassing pre-pandemic levels and projected further expansion in Canada.

COWZ
Pacer Funds Trust - Pacer US Cash Cows 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest COWZ News

COWZPacer Funds Trust - Pacer US Cash Cows 100 ETF